Exelixis, Inc. $EXEL Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 79.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,117,936 shares of the biotechnology company’s stock after acquiring an additional 495,247 shares during the period. BNP Paribas Financial Markets’ holdings in Exelixis were worth $48,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. RHS Financial LLC boosted its stake in shares of Exelixis by 2.4% during the fourth quarter. RHS Financial LLC now owns 12,619 shares of the biotechnology company’s stock worth $553,000 after buying an additional 293 shares during the period. Cim LLC boosted its stake in shares of Exelixis by 0.9% during the third quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after buying an additional 305 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Exelixis by 5.1% during the third quarter. EverSource Wealth Advisors LLC now owns 7,919 shares of the biotechnology company’s stock worth $327,000 after buying an additional 384 shares during the period. North Star Asset Management Inc. boosted its stake in shares of Exelixis by 0.7% during the third quarter. North Star Asset Management Inc. now owns 57,550 shares of the biotechnology company’s stock worth $2,377,000 after buying an additional 400 shares during the period. Finally, Spire Wealth Management boosted its stake in shares of Exelixis by 4.5% during the fourth quarter. Spire Wealth Management now owns 9,643 shares of the biotechnology company’s stock worth $423,000 after buying an additional 416 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Down 3.5%

Shares of Exelixis stock opened at $48.54 on Wednesday. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $52.96. The stock has a market cap of $12.20 billion, a PE ratio of 16.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.41. The company has a 50-day moving average of $46.19 and a two-hundred day moving average of $44.29.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The company had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. During the same period last year, the company posted $0.55 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. On average, sell-side analysts forecast that Exelixis, Inc. will post 3.18 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Dana Aftab sold 43,451 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the completion of the transaction, the executive vice president directly owned 594,741 shares of the company’s stock, valued at $29,945,209.35. This trade represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director George Poste sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the transaction, the director directly owned 118,832 shares of the company’s stock, valued at approximately $5,431,810.72. This trade represents a 33.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 205,433 shares of company stock valued at $9,930,259 in the last 90 days. 2.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright increased their price target on shares of Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Royal Bank Of Canada cut their price target on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a report on Monday, March 2nd. Morgan Stanley increased their price target on shares of Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Exelixis currently has an average rating of “Hold” and a consensus target price of $47.35.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.